Eliquis price slashed by Bristol Myers Squibb and Pfizer

New pricing initiative aims to cut out drug costs for patients.

Bristol Myers Squibb and Pfizer launch Eliquis at a steep discount

Bristol Myers Squibb and Pfizer announced a significant reduction in the price of their blood thinner drug, Eliquis. Starting September 8, patients will be able to buy Eliquis directly from the companies at a discounted price of $346 per month, down from approximately $606. This decision comes amid increasing pressure from the Trump administration over high drug prices and follows the trend of negotiating drug costs. Despite the discount, this price remains more than nine times the average out-of-pocket cost for insured patients. The companies argue the new pricing model seeks to improve patient access and transparency, though the price still exceeds negotiated rates set by Medicare, which will take effect next year.

This pricing strategy reflects a response to ongoing political pressure and shifts in healthcare funding. As pharmacies and insurance companies often serve as intermediaries, offering direct sales allows companies like Bristol Myers Squibb and Pfizer to control pricing while bypassing traditional market structures. However, the high end price may still alienate many patients despite the reduction. Analysts suggest that the initiative is not only a marketing drive but also a strategic pivot in light of potential regulatory changes under the current administration.

Highlights

This move may reshape the way pharmaceuticals are marketed and sold in the U.S.